Calgary/Edmonton, AB (May 4, 2026) The Pulmonary Hypertension Association of Canada (PHA Canada), along with expert physicians, are calling on Alberta to fund sotatercept (Winrevair), a new treatment for pulmonary arterial hypertension (PAH). “Pulmonary arterial hypertension is a rare, universally fatal disease involving high blood pressure in the blood vessels of the lungs, putting stress on the right side of the heart. This causes heart failure, shortness of breath with minimal activity,...

Two companies have announced good results from clinical trials in the past few weeks. Merck’s Phase 2 proof-of-concept CADENCE trial of two different doses of sotatercept for some Group 2 pulmonary hypertension patients succeeded. Trial participants had combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction (CpcPH-HFpEF). Participants who received sotatercept showed significant improvements in their pulmonary vascular resistance, which was...

April 7 is National Caregiver Day Many pulmonary hypertension patients have caregivers, whether they’re the partners, parents, or children of patients. Caregivers make a major difference in patients’ lives, helping them manage their pulmonary hypertension and daily routines. Nearly half of patients with pulmonary arterial hypertension rely on the help of a caregiver, underscoring just how essential this support truly is. Caregivers often take on a wide range of responsibilities—from managing...